Identification of a Specific Agonist of Human TAS2R14 from Radix Bupleuri Through Virtual Screening, Functional Evaluation and Binding Studies
Authors
Affiliations
Bitter taste receptors (TAS2Rs) have attracted a great deal of interest because of their recently described bronchodilator and anti-inflammatory properties. The aim of this study was to identify natural direct TAS2R14 agonists from Radix Bupleuri that can inhibit mast cell degranulation. A ligand-based virtual screening was conducted on a library of chemicals contained in compositions of Radix Bupleuri, and these analyses were followed by cell-based functional validation through a HEK293-TAS2R14-G16gust44 cell line and IgE-induced mast cell degranulation assays, respectively. Saikosaponin b (SSb) was confirmed for the first time to be a specific agonist of TAS2R14 and had an EC value of 4.9 μM. A molecular docking study showed that SSb could directly bind to a TAS2R14 model through H-bond interactions with Arg160, Ser170 and Glu259. Moreover, SSb showed the ability to inhibit IgE-induced mast cell degranulation, as measured with a β-hexosaminidase release model and real-time cell analysis (RTCA). In a cytotoxicity bioassay, SSb showed no significant cytotoxicity to HEK293 cells within 24 hours. This study demonstrated that SSb is a direct TAS2R14 agonist that inhibit IgE-induced mast cell degranulation. Although the target and in vitro bioactivity of SSb were revealed in this study, it still need in vivo study to further verify the anti-asthma activity of SSb.
Luongo F, Passaponti S, Haxhiu A, Bano I, Ponchia R, Morgante G Reprod Biol Endocrinol. 2025; 23(1):13.
PMID: 39863886 PMC: 11762455. DOI: 10.1186/s12958-025-01344-9.
Zhu Y, Lv X, Li R, Gao Z, Lei C, Wang L Adv Pharmacol Pharm Sci. 2024; 2024:2653426.
PMID: 39544485 PMC: 11561180. DOI: 10.1155/2024/2653426.
Li Y, Wu X, Ma Y, Xu L, Yang C, Peng D Front Chem. 2024; 11:1309965.
PMID: 38313222 PMC: 10834642. DOI: 10.3389/fchem.2023.1309965.
Bitter Phytochemicals as Novel Candidates for Skin Disease Treatment.
Gradinaru T, Vlad A, Gilca M Curr Issues Mol Biol. 2024; 46(1):299-326.
PMID: 38248322 PMC: 10814078. DOI: 10.3390/cimb46010020.
Dai R, Gao H, Su R Front Pharmacol. 2023; 14:1288363.
PMID: 38026989 PMC: 10661973. DOI: 10.3389/fphar.2023.1288363.